AR046601A1 - Uso de derivados 1- aminociclohexano para modificar la deposicion de peptidos ab fibrosos en amiloidopatias - Google Patents
Uso de derivados 1- aminociclohexano para modificar la deposicion de peptidos ab fibrosos en amiloidopatiasInfo
- Publication number
- AR046601A1 AR046601A1 ARP040103865A ARP040103865A AR046601A1 AR 046601 A1 AR046601 A1 AR 046601A1 AR P040103865 A ARP040103865 A AR P040103865A AR P040103865 A ARP040103865 A AR P040103865A AR 046601 A1 AR046601 A1 AR 046601A1
- Authority
- AR
- Argentina
- Prior art keywords
- aminocyclohexane derivative
- amyloidopathy
- peptides
- aminocyclohexane
- beta
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hydrogenated Pyridines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Uso de antagonistas del receptor de NMDA, tal como derivados 1-aminociclohexano como ejemplo: memantina, neramexano, entre otros para modificar la deposición de peptidos A beta potencialmente toxico y fibrosos en amiloidopatias. Específicamente, la invención se relaciona con la capacidad de la memantina para intervenir en el procesamiento de (APP) proteína precursora beta-amiloide y disminuir los niveles de peptidos A beta fibrosos. Reivindicación 1: Un método para disminuir el nivel de al menos un pcptido amiloide producido por una célula de mamífero, caracterizado porque dicho método comprende la administración a dicha célula de un derivado 1-aminociclohexano. Reivindicación 18: Un método para tratar, prevenir, detener, demorar el inicio y/o reducir el riesgo de desarrollar una amiloidopatia en un mamífero, caracterizado porque comprende la administración a dicho mamífero de una composición que comprende un derivado 1-aminociclohexano en cantidades eficaces para disminuir la cantidad de peptidos A beta en el cerebro, liquido cerebroespinal o plasma mamífero. Reivindicación 35: El método de la cláusula 18, caracterizado porque el derivado 1-aminociclohexano es administrado de forma simultánea o consecutiva con otro derivado 1-aminociclohexano, un inhibidor de acetilcolinesterasa (ACEI), un modificador de la secretasa o una combinación de los mismos. Reivindicación 37: Un método para controlar el tratamiento en un paciente que padece una amiloidopatia o que tiene riesgo de desarrollar una amiloidopatia, caracterizado porque comprende: proveer a dicho paciente una cantidad de un derivado 1-aminociclohexano, donde dicha cantidad disminuye los niveles de Abeta, y detectar un nivel de Abeta en el fluido corporal de dicho paciente que permita determinar la eficacia de dicho derivado 1-aminociclohexano. Reivindicación 44: El uso de un derivado 1-aminociclohexano, caracterizado porque es para la elaboración de un medicamento destinado a disminuir los niveles de Abeta en un fluido corporal o en el cerebro de un paciente.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US51370003P | 2003-10-22 | 2003-10-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR046601A1 true AR046601A1 (es) | 2005-12-14 |
Family
ID=34885905
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP040103865A AR046601A1 (es) | 2003-10-22 | 2004-10-22 | Uso de derivados 1- aminociclohexano para modificar la deposicion de peptidos ab fibrosos en amiloidopatias |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20050113458A1 (es) |
| EP (1) | EP1682109B1 (es) |
| JP (1) | JP2007509165A (es) |
| CN (1) | CN1870984A (es) |
| AR (1) | AR046601A1 (es) |
| AT (1) | ATE411015T1 (es) |
| AU (1) | AU2004316119B2 (es) |
| CA (1) | CA2540921A1 (es) |
| DE (1) | DE602004017207D1 (es) |
| IL (1) | IL174970A0 (es) |
| TW (1) | TW200526194A (es) |
| WO (1) | WO2005079779A1 (es) |
| ZA (1) | ZA200603231B (es) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7732162B2 (en) | 2003-05-05 | 2010-06-08 | Probiodrug Ag | Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases |
| US7619007B2 (en) | 2004-11-23 | 2009-11-17 | Adamas Pharmaceuticals, Inc. | Method and composition for administering an NMDA receptor antagonist to a subject |
| DE602006016934D1 (de) | 2005-04-06 | 2010-10-28 | Adamas Pharmaceuticals Inc | Verfahren und zusammensetzungen zur behandlung von zns-erkrankungen |
| US20070141148A1 (en) * | 2005-11-30 | 2007-06-21 | Merz Pharma Gmbh & Co. Kgaa | Neramexane MR matrix tablet |
| EP2089383B1 (en) | 2006-11-09 | 2015-09-16 | Probiodrug AG | 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases |
| DK2091948T3 (da) | 2006-11-30 | 2012-07-23 | Probiodrug Ag | Nye inhibitorer af glutaminylcyclase |
| GB0623897D0 (en) * | 2006-11-30 | 2007-01-10 | Pliva Istrazivanje I Razvoj D | Pharmaceutical composition of memantine |
| CA2679446C (en) | 2007-03-01 | 2016-05-17 | Probiodrug Ag | New use of glutaminyl cyclase inhibitors |
| RU2326660C1 (ru) * | 2007-03-14 | 2008-06-20 | Закрытое акционерное общество "Биологические исследования и системы" | Пероральный лекарственный препарат мемантин (варианты) и способ его получения (варианты) |
| US9656991B2 (en) | 2007-04-18 | 2017-05-23 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
| US20090118376A1 (en) * | 2007-11-02 | 2009-05-07 | Ru-Band Lu | Memantine Protects Inflammation-Related Degeneration of Dopamine Neurons Through Inhibition of Over-Activated Microglia and Release of Neurotrophic Factors from Astroglia |
| WO2009111611A2 (en) * | 2008-03-05 | 2009-09-11 | Proteotech Inc. | Compounds, compositions and methods for the treatment of islet amyloid polypeptide (iapp) accumulation in diabetes |
| ES2341517B1 (es) * | 2008-03-28 | 2011-01-25 | Farmalider, S.A | Utilizacion de un compuesto inhibidor de la activacion de la enzima erk 1/2 en el tratamiento de enfermedades neurodegenerativas. |
| MX2012002993A (es) | 2009-09-11 | 2012-04-19 | Probiodrug Ag | Derivados heterociclicos como inhibidores de ciclasa glutaminilo. |
| US20110236917A1 (en) * | 2009-11-17 | 2011-09-29 | Power3 Medical Products, Inc. | Diagnosis of Alzheimer's Disease |
| WO2011107530A2 (en) | 2010-03-03 | 2011-09-09 | Probiodrug Ag | Novel inhibitors |
| JP5688745B2 (ja) | 2010-03-10 | 2015-03-25 | プロビオドルグ エージー | グルタミニルシクラーゼ（ｑｃ、ｅｃ２．３．２．５）の複素環阻害剤 |
| EP2560953B1 (en) | 2010-04-21 | 2016-01-06 | Probiodrug AG | Inhibitors of glutaminyl cyclase |
| US9000047B2 (en) | 2010-05-24 | 2015-04-07 | Farmalider, S.A. | Compound inhibiting activation of the enzyme Erk 1/2 to be used in the treatment of neurodegenerative illnesses |
| NO3034079T3 (es) | 2010-11-15 | 2018-06-09 | ||
| ES2570167T3 (es) | 2011-03-16 | 2016-05-17 | Probiodrug Ag | Derivados de benzimidazol como inhibidores de glutaminil ciclasa |
| US10154971B2 (en) | 2013-06-17 | 2018-12-18 | Adamas Pharma, Llc | Methods of administering amantadine |
| NZ722077A (en) | 2013-12-20 | 2021-12-24 | Agenebio Inc | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
| AU2016279052A1 (en) | 2015-06-19 | 2018-02-15 | Agenebio, Inc. | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
| JP7174632B2 (ja) | 2016-06-23 | 2022-11-17 | コリウム， インコーポレイテッド | 親水性ドメインおよび疎水性ドメインならびに処置剤との接着剤マトリックス |
| EP3490541A2 (en) | 2016-07-27 | 2019-06-05 | Corium International, Inc. | Transdermal formulation and delivery method of low solubility or unstable unionized neutral drugs byin situ |
| MX2019001104A (es) | 2016-07-27 | 2019-10-02 | Corium Int Inc | Sistemas de suministro transdermico de memantina. |
| US20180028461A1 (en) | 2016-07-27 | 2018-02-01 | Corium International, Inc. | Transdermal delivery systems with pharmacokinetics bioequivalent to oral delivery |
| US20180170941A1 (en) | 2016-12-19 | 2018-06-21 | Agenebio, Inc. | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
| US11505555B2 (en) | 2016-12-19 | 2022-11-22 | Agenebio, Inc. | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
| US11548893B2 (en) | 2017-07-15 | 2023-01-10 | Arisan Therapeutics Inc. | Enantiomerically pure adamantane carboxamides for the treatment of filovirus infection |
| ES2812698T3 (es) | 2017-09-29 | 2021-03-18 | Probiodrug Ag | Inhibidores de glutaminil ciclasa |
| WO2019126531A1 (en) | 2017-12-20 | 2019-06-27 | Corium, Inc. | Transdermal adhesive composition comprising a volatile liquid therapeutic agent having low melting point |
| CN112601749B (zh) | 2018-06-19 | 2024-03-26 | 艾吉因生物股份有限公司 | 用于治疗认知损害的苯并二氮杂环庚三烯衍生物，组合物和方法 |
| WO2024039886A1 (en) | 2022-08-19 | 2024-02-22 | Agenebio, Inc. | Benzazepine derivatives, compositions, and methods for treating cognitive impairment |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3691016A (en) * | 1970-04-17 | 1972-09-12 | Monsanto Co | Process for the preparation of insoluble enzymes |
| CH603545A5 (es) * | 1972-04-20 | 1978-08-31 | Merz & Co | |
| CA1023287A (en) * | 1972-12-08 | 1977-12-27 | Boehringer Mannheim G.M.B.H. | Process for the preparation of carrier-bound proteins |
| US4195128A (en) * | 1976-05-03 | 1980-03-25 | Bayer Aktiengesellschaft | Polymeric carrier bound ligands |
| US4330440A (en) * | 1977-02-08 | 1982-05-18 | Development Finance Corporation Of New Zealand | Activated matrix and method of activation |
| CA1093991A (en) * | 1977-02-17 | 1981-01-20 | Hideo Hirohara | Enzyme immobilization with pullulan gel |
| US4229537A (en) * | 1978-02-09 | 1980-10-21 | New York University | Preparation of trichloro-s-triazine activated supports for coupling ligands |
| DE2856393C2 (de) * | 1978-12-27 | 1983-04-28 | Merz + Co GmbH & Co, 6000 Frankfurt | Arzneimittel zur Behandlung von Morbus Parkinson |
| US5366738A (en) * | 1982-07-29 | 1994-11-22 | Merck & Co., Inc. | Controlled release drug dispersion delivery device |
| US4503030A (en) * | 1983-06-06 | 1985-03-05 | Alza Corporation | Device for delivering drug to certain pH environments |
| US4615698A (en) * | 1984-03-23 | 1986-10-07 | Alza Corporation | Total agent osmotic delivery system |
| US4737456A (en) * | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
| US4666829A (en) * | 1985-05-15 | 1987-05-19 | University Of California | Polypeptide marker for Alzheimer's disease and its use for diagnosis |
| US5811128A (en) * | 1986-10-24 | 1998-09-22 | Southern Research Institute | Method for oral or rectal delivery of microencapsulated vaccines and compositions therefor |
| US4849222A (en) * | 1987-03-24 | 1989-07-18 | The Procter & Gamble Company | Mixtures for treating hypercholesterolemia |
| JP2670680B2 (ja) * | 1988-02-24 | 1997-10-29 | 株式会社ビーエムジー | 生理活性物質含有ポリ乳酸系微小球およびその製造法 |
| ATE94384T1 (de) * | 1989-04-14 | 1993-10-15 | Merz & Co Gmbh & Co | Verwendung von adamantan-derivaten zur praevention und behandlung der cerebralen ischaemie. |
| US5912410A (en) * | 1990-06-15 | 1999-06-15 | Scios Inc. | Transgenic non-human mice displaying the amyloid-forming pathology of alzheimer's disease |
| US5614560A (en) * | 1991-04-04 | 1997-03-25 | Children's Medical Center Corporation | Method of preventing NMDA receptor-mediated neuronal damage |
| US5955317A (en) * | 1993-01-25 | 1999-09-21 | Takeda Chemical Industries, Ltd. | Antibodies to β-amyloids or their derivatives and use thereof |
| CZ293248B6 (cs) * | 1997-06-30 | 2004-03-17 | Merz Pharma Gmbh & Co. Kgaa | 1-Aminocyklohexanový derivát a farmaceutická kompozice na jeho bázi |
| US6080778A (en) * | 1998-03-23 | 2000-06-27 | Children's Medical Center Corporation | Methods for decreasing beta amyloid protein |
| GB0018272D0 (en) * | 2000-07-25 | 2000-09-13 | Vernalis Research Limited | Chemical compounds IV |
| US20040102525A1 (en) * | 2002-05-22 | 2004-05-27 | Kozachuk Walter E. | Compositions and methods of treating neurological disease and providing neuroprotection |
| AU2003251993A1 (en) * | 2002-07-19 | 2004-02-09 | Inge Grundke-Iqbal | NMDA RECEPTOR ANTAGONISTS AND THEIR USE IN INHIBITING ABNORMAL HYPERPHOSPHORYLATION OF MICROTUBULE ASSOCIATED PROTEIN tau |
| TW200418446A (en) * | 2002-10-24 | 2004-10-01 | Merz Pharma Gmbh & Co Kgaa | Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors |
-
2004
- 2004-10-22 US US10/971,306 patent/US20050113458A1/en not_active Abandoned
- 2004-10-22 AT AT04821452T patent/ATE411015T1/de not_active IP Right Cessation
- 2004-10-22 CA CA002540921A patent/CA2540921A1/en not_active Abandoned
- 2004-10-22 AU AU2004316119A patent/AU2004316119B2/en not_active Expired - Fee Related
- 2004-10-22 CN CNA2004800311081A patent/CN1870984A/zh active Pending
- 2004-10-22 JP JP2006536825A patent/JP2007509165A/ja not_active Withdrawn
- 2004-10-22 DE DE602004017207T patent/DE602004017207D1/de not_active Expired - Fee Related
- 2004-10-22 EP EP04821452A patent/EP1682109B1/en active Active
- 2004-10-22 AR ARP040103865A patent/AR046601A1/es not_active Application Discontinuation
- 2004-10-22 TW TW093132253A patent/TW200526194A/zh unknown
- 2004-10-22 WO PCT/US2004/035040 patent/WO2005079779A1/en active Application Filing
-
2006
- 2006-04-11 IL IL174970A patent/IL174970A0/en unknown
- 2006-04-21 ZA ZA200603231A patent/ZA200603231B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN1870984A (zh) | 2006-11-29 |
| ZA200603231B (en) | 2007-11-28 |
| DE602004017207D1 (de) | 2008-11-27 |
| WO2005079779A1 (en) | 2005-09-01 |
| US20050113458A1 (en) | 2005-05-26 |
| EP1682109B1 (en) | 2008-10-15 |
| EP1682109A1 (en) | 2006-07-26 |
| ATE411015T1 (de) | 2008-10-15 |
| CA2540921A1 (en) | 2005-09-01 |
| AU2004316119A1 (en) | 2005-09-01 |
| AU2004316119B2 (en) | 2008-04-24 |
| JP2007509165A (ja) | 2007-04-12 |
| TW200526194A (en) | 2005-08-16 |
| IL174970A0 (en) | 2006-08-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR046601A1 (es) | Uso de derivados 1- aminociclohexano para modificar la deposicion de peptidos ab fibrosos en amiloidopatias | |
| Jessop et al. | Autophagy deficiency in macrophages enhances NLRP3 inflammasome activity and chronic lung disease following silica exposure | |
| Hoefert et al. | Importance of microcracks in etiology of bisphosphonate-related osteonecrosis of the jaw: a possible pathogenetic model of symptomatic and non-symptomatic osteonecrosis of the jaw based on scanning electron microscopy findings | |
| AR071732A1 (es) | Metodos para tratar la enfermedad de alzheimer, reducir la disminucion del volumen cerebral y monitorear una poblacion de pacientes que experimentan tratamiento o profilaxis para una enfermedad, uso de una medida de numero de copia apoe4, forma humanizada de un anticuerpo y acido nucleico aislado. | |
| CY1119122T1 (el) | Θεραπευτικη αναπληρωση και εμπλουτισμος της λιπανσεως της οφθαλμικης επιφανειας | |
| BR112012018500A2 (pt) | alguns inibidores de quinurenina-3-monooxigenase, composições farmacêuticas e métodos de uso destas | |
| PE20040134A1 (es) | Forma de dosificacion de una vez al dia de pramipexol | |
| BR0316050A (pt) | Métodos de tratar, controlar ou prevenir um câncer especìfico e doença associada com angiogênese indesejada e de reduzir ou evitar um efeito adverso associado com a administração de um segundo ingrediente ativo e com terapia de radiação, terapia hormonal, terapia biológica, ou imunoterapia em um paciente sofrendo de um câncer especìfico, composição farmacêutica e kit | |
| ATE535257T1 (de) | Ophthalmologische formulierung mit methylsulfonylmethan und ciprofloxacin | |
| WO2014018563A2 (en) | Methods for the treatment of cancer | |
| AR058620A1 (es) | Formulacion farmaceutica para el suministro de compuestos inhibidores del receptor de tirosina quinasa (rtki) al ojo | |
| LoCoco et al. | Pharmacological augmentation of nicotinamide phosphoribosyltransferase (NAMPT) protects against paclitaxel-induced peripheral neuropathy | |
| MXPA05012155A (es) | Metodos y composiciones que utilizan compuestos inmunomoduladores para el tratamiento y manejo de canceres y otras enfermedades. | |
| BRPI0416752A (pt) | composição farmacêutica, uso de um ou mais compostos, método para a prevenção ou tratamento de distúrbios, compostos, e, processo para a preparação de uma composição farmacêutica | |
| EA201490279A1 (ru) | Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения | |
| BRPI0607168A2 (pt) | terapia de combinação parenteral, composição farmacêutica, processo para preparar uma composição farmacêutica e método de tratamento | |
| BRPI0416260A (pt) | método para tratar, prevenir ou controlar uma doença ou distúrbio relacionada com amianto, e, composição farmacêutica | |
| MA32458B1 (fr) | Combinaison d'un antagoniste de c-met et d'un compose aminoheteroaryle pour le traitement d'un cancer | |
| BRPI0519656A2 (pt) | terapia de combinaÇço compreendendo telmisartan e hidroclorotiazida | |
| BRPI0418742A (pt) | métodos de tratamento, prevenção ou controle de uma sìndrome mielodisplásica, de redução ou evitação de um efeito adverso associado com a administração de um segundo ingrediente ativo em um paciente sofrendo de um sìndrome mielodisplásica, composição farmacêutica, forma de dosagem unitária única, e, kit | |
| AU2009246603A8 (en) | Von willebrand factor (vwf) inhibitors for treatment or prevention of infarction | |
| AR085934A1 (es) | Tratamiento de mieloma multiple con masitinib | |
| CL2016001707A1 (es) | Tratamiento de trastornos congnitivos con (r)-7-cloro-n-(quinuclidin-3-il) benzo(b)tiofeno-2-carboxamida y sales farmacéuticamente aceptables de la misma (div. sol. 1178-11). | |
| JP2002508321A (ja) | 抗腫瘍薬としての使用のための多触媒性プロテアーゼ阻害剤 | |
| UY32600A (es) | Formulación en lípidos de un promotor de la apoptosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |